Kontafarma China Holdings Ltd (HK:1312)
:1312
Top Page
Kontafarma China Holdings Ltd
(1312)
Select Model
Select Model
Rating:44Neutral
Price Target:
HK$0.03
▼(-3.33% Downside)
Action:ReiteratedDate:11/22/25
Kontafarma China Holdings Ltd receives an overall stock score of 44, primarily driven by weak financial performance with ongoing losses and declining cash flow growth, despite some revenue growth and balance sheet stability. Valuation concerns due to a negative P/E ratio further weigh on the score, while technical indicators remain neutral with no strong bullish or bearish signals.
Positive Factors
Market Demand
The increasing demand for healthcare products in China provides a strong market opportunity for Kontafarma, supporting potential long-term revenue growth.
Negative Factors
Profitability Issues
Persistent profitability challenges and declining revenues indicate difficulties in maintaining market share and pricing power, affecting long-term sustainability.
Read all positive and negative factors
Positive Factors
Negative Factors
Market Demand
The increasing demand for healthcare products in China provides a strong market opportunity for Kontafarma, supporting potential long-term revenue growth.
Read all positive factors
Kontafarma China Holdings Ltd (1312) vs. iShares MSCI Hong Kong ETF (EWH)
Market Cap
HK$167.36M
Dividend YieldN/A
Average Volume (3M)9.95M
Price to Earnings (P/E)―
Beta (1Y)0.14
Revenue Growth6.55%
EPS Growth-475.22%
CountryHK
Employees714
SectorHealthcare
Sector Strength45
IndustryConstruction Materials
Share Statistics
EPS (TTM)N/A
Shares Outstanding5,588,572,000
10 Day Avg. Volume1,701,000
30 Day Avg. Volume9,954,100
Financial Highlights & Ratios
PEG Ratio-0.01
Price to Book (P/B)0.15
Price to Sales (P/S)0.16
P/FCF Ratio4.34
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)N/A
Revenue Forecast (FY)N/A
Kontafarma China Holdings Ltd Business Overview & Revenue Model
Company Description
Kontafarma China Holdings Ltd. engages in the manufacture and sale of cement. It operates through the following segments: Pharmaceutical and Fitness Business. The Pharmaceutical Business segment involves in manufacture and sales of prescription dr...
How the Company Makes Money
Kontafarma generates revenue through multiple streams, primarily from the sale of pharmaceutical products, which includes both prescription and over-the-counter medications. The company capitalizes on its extensive distribution network to reach ho...
Kontafarma China Holdings Ltd Financial Statement Overview
Summary
Income Statement
35
Negative
Balance Sheet
50
Neutral
Cash Flow
40
Negative
| Breakdown | TTM | Dec 2024 | Dec 2023 | Dec 2022 | Dec 2021 | Dec 2020 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 891.73M | 897.52M | 809.11M | 894.06M | 803.27M | 1.01B |
| Gross Profit | 493.63M | 516.16M | 471.29M | 506.22M | 396.18M | 555.75M |
| EBITDA | -79.14M | -49.93M | 78.50M | 26.93M | 112.18M | 156.31M |
| Net Income | -362.77M | -75.54M | -28.84M | -41.55M | -15.05M | -267.16M |
Balance Sheet | ||||||
| Total Assets | 1.15B | 1.59B | 1.73B | 2.12B | 2.56B | 2.54B |
| Cash, Cash Equivalents and Short-Term Investments | 78.33M | 90.58M | 87.66M | 142.59M | 183.96M | 194.79M |
| Total Debt | 235.86M | 297.19M | 333.82M | 590.72M | 728.95M | 782.61M |
| Total Liabilities | 532.12M | 625.90M | 665.39M | 964.16M | 1.22B | 1.19B |
| Stockholders Equity | 684.99M | 978.70M | 1.06B | 1.10B | 1.19B | 1.21B |
Cash Flow | ||||||
| Free Cash Flow | 32.13M | 33.41M | 12.92M | -53.84M | -49.31M | 51.02M |
| Operating Cash Flow | 49.63M | 47.05M | 37.12M | -2.17M | 75.07M | 206.93M |
| Investing Cash Flow | 6.74M | -6.01M | 144.14M | 121.53M | 23.24M | -206.12M |
| Financing Cash Flow | -35.78M | -42.52M | -198.81M | -137.33M | -99.80M | 19.10M |
Kontafarma China Holdings Ltd Technical Analysis
Negative
0.03
Price Trends
0.03
Negative
0.03
Positive
0.03
Negative
Market Momentum
>-0.01
Negative
46.74
Neutral
100.00
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For HK:1312, the sentiment is Negative. The current price of 0.03 is below the 20-day moving average (MA) of 0.03, below the 50-day MA of 0.03, and below the 200-day MA of 0.03, indicating a bearish trend. The MACD of >-0.01 indicates Negative momentum. The RSI at 46.74 is Neutral, neither overbought nor oversold. The STOCH value of 100.00 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Negative sentiment for HK:1312.
Kontafarma China Holdings Ltd Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
54 Neutral | HK$198.90M | -0.15 | -30.35% | ― | -11.89% | -290.48% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
49 Neutral | HK$911.68M | -2.84 | -48.86% | ― | -43.46% | -96.48% | |
48 Neutral | HK$673.79M | -3.17 | 20.98% | ― | ― | ― | |
48 Neutral | HK$159.80M | -38.07 | -8.95% | ― | 2.54% | 33.33% | |
44 Neutral | HK$167.36M | -0.14 | -43.61% | ― | 6.55% | -475.22% | |
42 Neutral | HK$165.83M | -4.22 | -36.23% | ― | -17.32% | 55.74% |
* Healthcare Sector Average
HK:1312
Kontafarma China Holdings Ltd
0.03
<0.01
7.14%
HK:0858
Extrawell Pharmaceutical Holdings Limited
0.08
0.03
73.33%
HK:1011
China NT Pharma Group Co., Ltd.
0.71
0.47
195.83%
HK:1498
PuraPharm Corp. Ltd.
0.31
-0.26
-45.61%
HK:1652
Fusen Pharmaceutical Co., Ltd.
1.24
0.94
313.33%
HK:8622
Huakang Biomedical Holdings Company Limited
0.31
0.00
0.00%
Kontafarma China Holdings Ltd Corporate Events
Kontafarma China Tightens Audit Committee Mandate to Bolster Governance and Oversight
Dec 29, 2025
Kontafarma China Holdings Ltd has formalised updated terms of reference for its Audit Committee, stipulating that it must comprise at least three non-executive directors, with a majority being independent non-executive directors and at least one m...
Kontafarma Sets Formal Terms for Remuneration Committee to Strengthen Governance
Dec 29, 2025
Kontafarma China Holdings Ltd has set out the formal terms of reference for its board remuneration committee, which is composed entirely of non-executive directors with a majority of independent non-executive directors and chaired by an independen...
Kontafarma Announces Change in Shareholding Structure
Dec 5, 2025
Kontafarma China Holdings Ltd has announced a change in the shareholding structure of its controlling shareholder. The People’s Government of Shanxi Province has decided to transfer significant equity interests in Shanxi Construction Investm...
Kontafarma Announces Executive Resignation
Nov 14, 2025
Kontafarma China Holdings Limited announced the resignation of Ms. Qiao Linna from her roles as an executive director and vice president, effective November 14, 2025. Ms. Qiao’s departure also results in her cessation as a member of the comp...
Kontafarma China Holdings Ltd Announces Board Restructuring
Nov 14, 2025
Kontafarma China Holdings Ltd has announced a restructuring of its board of directors, effective November 14, 2025. The company has appointed Wang Feifei as Chairman and President, with Guo Zixiu as Financial Controller, and Liu Jiankun as an Exec...
Kontafarma China Approves Major R&D Construction Contract
Nov 7, 2025
Kontafarma China Holdings Ltd announced that its adjourned extraordinary general meeting successfully passed all proposed resolutions, including the approval of a significant construction contract for a research and development complex in Beijing....
Kontafarma China Holdings Ltd Reschedules Extraordinary General Meeting
Oct 16, 2025
Kontafarma China Holdings Ltd has announced the adjournment of its Extraordinary General Meeting (EGM) initially scheduled for October 20, 2025, to November 7, 2025, due to the need for additional preparation time. The venue remains unchanged, and...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.